Breaking News Instant updates and real-time market news.

DBVT

DBV Technologies

$9.45

0.75 (8.62%)

, KPTI

Karyopharm

$8.90

2.37 (36.29%)

08:57
07/05/19
07/05
08:57
07/05/19
08:57

Fly Intel: Pre-market Movers

HIGHER: DBV Technologies (DBVT), up 16% after Bloomberg reports there are expectations that the company will submit another biologic license application for its Viaskin Peanuts allergy patch to the FDA sometime during Q3... Karyopharm (KPTI), up 12% after the FDA approved oral Xpovio, a nuclear export inhibitor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents and an anti-CD38 monoclonal antibody... Grifols (GRFS), up 4% after announcing that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the FDA. LOWER: Qualcomm (QCOM), down 3% after Bloomberg reported the company lost in its attempt to put on pause a U.S. judge's ruling that the company engaged in anti-competitive practices as Qualcomm pursues an appeal... Celyad (CYAD), down 5% after reporting preliminary interim data from the ongoing SHRINK and alloSHRINK Phase 1 trials assessing safety and clinical activity of the NKG2D-based CAR-T therapies CYAD-01 and CYAD-101 for the treatment of metastatic colorectal cancer... Senseonics (SENS), down 3% after Raymond James analyst Jayson Bedford downgraded the stock to Market Perform from Outperform. The analyst says the company's "persistent headwinds" leave him "less patient" with respect to the shares.

DBVT

DBV Technologies

$9.45

0.75 (8.62%)

KPTI

Karyopharm

$8.90

2.37 (36.29%)

GRFS

Grifols

$21.38

0.32 (1.52%)

QCOM

Qualcomm

$74.65

-2.36 (-3.06%)

CYAD

Celyad

$13.30

-0.11 (-0.82%)

SENS

Senseonics

$1.88

-0.05 (-2.59%)

  • 05

    Jul

  • 06

    Jul

  • 09

    Jul

  • 09

    Jul

  • 30

    Jul

  • 31

    Jul

  • 09

    Sep

DBVT DBV Technologies
$9.45

0.75 (8.62%)

05/20/19
FBCO
05/20/19
INITIATION
Target $30
FBCO
Outperform
Aimmune assumed with an Outperform at Credit Suisse
Credit Suisse analyst Evan Seigerman assumed coverage of Aimmune Therapeutics (AIMT) with an Outperform rating and lowered the price target on the stock to $30 from the firm's prior $36 target, citing his belief that AR101 is likely to be approved to reduce risk from exposure in children and adults with peanut allergy. Aimmune's only competitor in peanut allergy treatment, DBV Therapeutics (DBVT), is at least a year behind in his view, Seigerman tells investors.Target $30.
06/17/19
06/17/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DBV Technologies (DBVT) initiated with a Buy at Goldman Sachs. 2. Amicus (FOLD) initiated with a Buy at H.C. Wainwright. 3. Viper Energy (VNOM) initiated with a Buy at SunTrust. 4. GNC Holdings (GNC) initiated with a Hold at Jefferies. 5. Eventbrite (EB) initiated with an Outperform at William Blair. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/17/19
GSCO
06/17/19
INITIATION
Target $14
GSCO
Buy
DBV Technologies initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh started DBV Technologies (DBVT) with a Buy rating and $14 price target. DBVT is a late-stage specialty biotech company, with a proprietary technology platform that could be used to treat a range of food allergies, Suvannavejh tells investors in a research note. The analyst sees 66% upside from current share levels given the potential catalysts over the next 18 months, which include the Biologics License Applications re-filing in Q3 and FDA acceptance in Q4, a potential panel hearing in mid-2020, and likely final U.S. approval by the end of 2020. Suvannavejh sees an 85% probability of success for DBV's Viaskin Peanut and views the treatment as a more compelling option versus Aimmune's (AIMT) AR101 on overall safety and product presentation profiles.
04/10/19
STFL
04/10/19
NO CHANGE
STFL
Hold
ICER draft report presents modest headwind for DBV, Aimmune, says Stifel
Stifel analyst Derek Archila noted that ICER, an independent and non-partisan research organization that analyzes the benefits along with costs of treatments, issued a draft report assessing the value and effectiveness of Aimmune's (AIMT) AR101 and DBV Technologies' (DBVT) Viaskin peanut for peanut allergy. He believes ICER's cost-effectiveness analysis re-affirms his cautious approach on the peanut immunotherapy category and believes the report presents a modest headwind for the stocks. However, this was only a draft report in which ICER made assumptions for costs since no official pricing has been announced for either therapy, Archlia noted. He maintains Hold ratings on both Aimmune and DBV Technologies.
KPTI Karyopharm
$8.90

2.37 (36.29%)

06/14/19
HCWC
06/14/19
NO CHANGE
Target $29
HCWC
Buy
Karyopharm EHA Phase 1b/2 combination data 'encouraging,' says H.C. Wainwright
H.C. Wainwright analyst Edward White maintained a Buy rating and $29 price target on Karyopharm, saying the company presented "encouraging" early Phase 1b/2 selinexor combination data from the STOMP trial in relapsed or refractory multiple myeloma patients at the European Hematological Association 2019 Annual Meeting. In a research note to investors, White says the updated selinexor with Darzalex data "continues to look good," with efficacy results showing an overall response rate of 73% in Darzalex naive patients versus the EHA abstract data published last month with an ORR of 77%. Looking ahead, White projects revenues of $189M and $241M for selinexor in penta-refractory multiple myeloma and DLBCL, respectively, in 2026. For selinexor in combination multiple myeloma treatment, he forecasts revenues of $332M in 2026, and for selinexor in solid tumors he sees revenues of $241M in 2026.
07/05/19
WEDB
07/05/19
NO CHANGE
Target $11
WEDB
Outperform
Wedbush boosts Karyopharm target to $11 from $6 on Xpovio approval
Wedbush analyst David Nierengarten raised his price target for Karyopharm Therapeutics to $11 from $6 after the FDA on Wednesday approved selinexor, now branded as Xpovio, in combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least four prior therapies. The stock closed Wednesday up 36% to $8.90. The label has no black box warnings or contraindications, but does include extensive safety monitoring guidelines and recommendations, Nierengarten tells investors in a research note. Karyopharm has priced Xpovio at $22,000 per month, which comes in higher than expected but is "not unreasonable" in comparison to other FDA-approved multiple myeloma drugs, contends the analyst. He projects sales of $9.1M in fiscal 2019, with peak sales potential approaching $300M. Nierengarten keeps an Outperform rating on Karyopharm Therapeutics.
07/05/19
HCWC
07/05/19
NO CHANGE
Target $32
HCWC
Buy
Karyopharm approval label for Xpovio 'compelling,' says H.C. Wainwright
Karyopharm Therapeutics on Wednesday, three days before the action date date, announced that the FDA granted accelerated approval for Xpovio n relapsed or refractory multiple myeloma patients who have received at least four prior therapies and whose disease was refractory after at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody, H.C. Wainwright analyst Edward White tells investors in a research note. Further, there is not a black box warning or contraindications in the Xpovio label, adds the analyst. He finds the label "compelling and inline with expectations." White estimates Xpovio in the penta-refractory setting will have sales of $5.5less than this year rising to $123.8M in 2026. He keeps a Buy rating on Karyopharm Therapeutics with a $32 price target.
03/15/19
WEDB
03/15/19
NO CHANGE
WEDB
Wedbush views Karyopharm 's PDUFA date extension as a positive
Wedbush analyst David Nierengarten maintained an Outperform rating and $6 price target on Karyopharm. In a note titled "FDA Extends PDUFA by Three Months," he said he is inclined to view the extension as a positive for the company "given the negative sentiment on the name and general belief that an April 6, 2019 approval was unlikely."
GRFS Grifols
$21.38

0.32 (1.52%)

01/23/19
HCWC
01/23/19
NO CHANGE
Target $8
HCWC
Buy
H.C. Wainwright boosts Rigel target to $8 on European partnership
H.C. Wainwright analyst Joseph Pantginis raised his price target for Rigel Pharmaceuticals to $8 from $7.50 saying the company checked an "important box" by signing a partnership for Europe with Grifols (GRFS). The analyst is "pleased" with the Grifols partnership and the terms, "especially the royalty." He's confident Rigel is working on different fronts to boost fostamatinib's clinical and commercial potential outside the U.S. and reiterates a Buy rating on the shares.
02/08/19
BREN
02/08/19
DOWNGRADE
BREN
Hold
Grifols downgraded to Hold from Buy at Berenberg
06/27/19
06/27/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Owens Corning (OC) upgraded to Buy from Neutral at BofA/Merrill and to Neutral from Sell at Seaport Global. 2. Grifols (GRFS) upgraded to Overweight from Neutral at JPMorgan with analyst James Gordon saying sales growth and margin expansion will drive a re-rating in the shares. 3. Arch Capital (ACGL) upgraded to Buy from Hold at Deutsche Bank with analyst Joshua Shanker saying his increased 2020 EPS estimate of $3.00 represents the high on the Street. 4. KB Home (KBH) upgraded to Buy from Neutral at Buckingham and to Overweight from Sector Weight at KeyBanc. 5. TripAdvisor (TRIP) upgraded to Buy from Neutral at DA Davidson with analyst Tom White saying TripAdvisor's business has been getting steadily healthier over the last several quarters as new products improve revenue quality by diversifying its customer base, adding that these trends, along with stability in TripAdvisor's core hotel CPC auction and valuation multiples 20%+ below historical averages reduces its risk profile and creates a compelling entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/27/19
JPMS
06/27/19
UPGRADE
Target $22.5
JPMS
Overweight
Grifols upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded Grifols to Overweight from Neutral and raised his price target for the shares to $22.50 from $21. Sales growth and margin expansion will drive a re-rating in the shares, Gordon tells investors in a research note. The analyst believes Grifols' sales growth and profitability are at an inflection point. Further, consensus expectations are achievable, the company's competition more distant, and its valuation is undemanding, according to Gordon. He believes the company can achieve low double digit EBITDA and mid-teens earrings growth over the medium-term.
QCOM Qualcomm
$74.65

-2.36 (-3.06%)

06/11/19
RAJA
06/11/19
NO CHANGE
RAJA
Broadcom, Apple deal closes door on Qualcomm/Qorvo, says Raymond James
Raymond James analyst Chris Caso notes that Broadcom (AVGO) disclosed that it had signed a 2-year contract with Apple (AAPL) for the sale of RF components, similar to a 3-year contract between Broadcom and Apple signed in 2016 but now with the latter sourcing "all of its requirements for such RF front end components and modules" from Broadcom. The analyst believes this closes the door on Qualcomm (QCOM) getting RF content in the 2020 iPhone, while maintaining the status quo for Skyworks (SWKS), which supplied the low band PAD and diversity receive through the term of the last Broadcom/Apple contract. Additionally, Caso thinks the Broadcom agreement also closes the door on the mid/high band opportunity at Apple for Qorvo (QRVO) through 2020.
05/23/19
05/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) downgraded to Neutral from Buy at Mizuho with analyst Vijay Rakesh saying he is moving to the sidelines given the "uncertainty" with Judge Koh's Federal Trade Commission ruling on Qualcomm. 2. Chipotle (CMG) and Bloomin' Brands (BLMN) downgraded to Underperform from Market Perform at BMO Capital. 3. Sasol (SSL) downgraded to Neutral from Buy at Citi and to Neutral from Overweight at JPMorgan. 4. Expedia (EXPE) downgraded to Neutral from Buy at Citi with analyst Mark May saying Vrbo's growth has "disappointed and slowed meaningfully," and this could weight on Expedia's overall growth. 5. NetApp (NTAP) downgraded to Buy from Conviction Buy at Goldman Sachs and to Hold from Buy at Lake Street. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/18/19
MSCO
06/18/19
NO CHANGE
Target $95
MSCO
Overweight
Qualcomm share ownership 'still worth the noise,' says Morgan Stanley
Morgan Stanley analyst James Faucette said being a Qualcomm (QCOM) shareholder has "always required a bit more mettle" given its history of political and legal risks, but he thinks that at current levels the stock is "still worth the noise." Faucette reduced his FY19 and FY20 estimates slightly because he no longer assumes Apple (AAPL) will refresh its portfolio to include more Qualcomm-based legacy models in late 2019 and most of FY20 and also to be more conservative in his assumption of Huawei's contribution. However, he is now modeling more impact from an uplift in 5G average selling prices and thinks if Huawei handsets are absorbed by other OEMs that Qualcomm could see a positive impact, Faucette noted. The analyst, who projects Qualcomm's FY21 earnings at about $6.80 per share, keeps an Overweight rating and $95 price target on the stock.
06/06/19
LEHM
06/06/19
NO CHANGE
Target $90
LEHM
Overweight
Qualcomm price target lowered to $90 from $100 at Barclays
Barclays analyst Blayne Curtis lowered his price target for Qualcomm to $90 from $100 to reflect the removal of Huawei from his model. The analyst, however, keeps an Overweight rating on the shares.
CYAD Celyad
$13.30

-0.11 (-0.82%)

06/17/19
PIPR
06/17/19
NO CHANGE
PIPR
Piper Jaffray reiterates Overweight on Celyad after EHA update
Piper Jaffray analyst Edward Tenthoff reiterated an Outperform rating and $41 price target on Celyad after the company presented updated data for Phase I THINK and DEPLETHINK at the European Hematology Association, or EHA. Tenthoff noted that the updated Phase I THINK study now shows 4/13, or 31%, evaluable r/r AML patients achieved objective responses on CYAD-01 monotherapy without preconditioning with manageable safety, while the Phase I DEPLETHINK study demonstrated 2/5 evaluable patients achieved SD on CYAD-01 with pre-conditioning regiment of cyclphosphamide and fludarabine at the same three dose level as in THINK. The analyst added that Celyad could potentially initiate a registrational Phase II AML study in the second half of the year.
03/29/19
HCWC
03/29/19
NO CHANGE
HCWC
Celyad CFO transitioning to CEO 'a positive,' says H.C. Wainwright
H.C. Wainwright analyst Edward White maintained a Buy rating and $52 price target on Celyad after the company reported FY18 results and announced its CFO was transitioning to CEO. The analyst noted that the company reported revenue above its estimate, although reporting EPS below its estimate. Additionally, Celyad reiterated that it had enough cash and investments to fund through mid-2020. White believes Filippo Petti's transition to CEO should "likely be well accepted by investors" and "is a positive for the company."
04/01/19
PIPR
04/01/19
NO CHANGE
PIPR
Celyad price target lowered to $41 from $51 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating on Celyad, but lowered his price target on shares to $41 from $51 as he pushes out approvals based on clinical progress. The analyst noted that Celyad intends to initiate a potentially registrational Phase II AML study in the second half of 2019, has begun a Phase I study of allogeneic CYAD-101 in mCRC with data in the second half of 2019, and will file INDs on CYAD-211 BCMA and CYAD-221 CD-19 CAR-Ts in 2020.
06/17/19
RHCO
06/17/19
NO CHANGE
RHCO
Celyad selloff a buying opportunity, says SunTrust
SunTrust analyst Peter Lawson reiterated a Buy rating and $45 price target on Celyad after the stock dropped by almost 29% post-EHA, or European Hematology Association. The analyst sees this as a buying opportunity, as he believes it is undervalued, and also believes the year-end data is more important to the stock than the current headline data, which he said is "too early" and doesn't warrant a selloff.
SENS Senseonics
$1.88

-0.05 (-2.59%)

01/29/19
PIPR
01/29/19
INITIATION
Target $2.7
PIPR
Neutral
Senseonics initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst JP McKim started Senseonics with a Neutral rating and $2.70 price target. The analyst believes the stock's risk/reward remains balanced over the next 12 months given the "hand to hand combat of reimbursement coverage and at its current 90 day configuration in the U.S."
02/04/19
PIPR
02/04/19
NO CHANGE
Target $2.7
PIPR
Neutral
Piper Jaffray uncertain of benefits from increased Roche access for Senseonics
Piper Jaffray analyst JP Kim kept his Neutral rating and $2.70 price target on Senseonics (SENS) after the company announced an extension of agreement with Roche (RHHBY). The analyst notes that the management is likely willing to trade off the near term price gains for long term volume gain through this deal, but adds that a reset of consensus estimates for sales that would lead to Senseonics becoming a "beat and raise story" is uncertain.
07/05/19
RAJA
07/05/19
DOWNGRADE
RAJA
Market Perform
Senseonics downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Jayson Bedford downgraded Senseonics to Market Perform from Outperform. The analyst says the company's "persistent headwinds" leave him "less patient" with respect to the shares.
06/06/19
PIPR
06/06/19
NO CHANGE
PIPR
Senseonics receives FDA claim for Eversense CGM system, says Piper Jaffray
Piper Jaffray analyst JP McKim maintained a Neutral rating and $2.70 price target on Senseonics, while noting that the company "received a non-adjunctive claim for their Eversense CGM system" from the FDA. The analyst said that the claim would allow Eversense "to be used in replacement for finger stick glucose measurements" and added that it "is a needed claim to begin the process to unlock the Medicare population and represents an important stage in their commercialization process."

TODAY'S FREE FLY STORIES

04:10
07/17/19
07/17
04:10
07/17/19
04:10
General news
FX Action: USD-CAD printed a five-session high »

FX Action: USD-CAD…

02:55
07/17/19
07/17
02:55
07/17/19
02:55
General news
FX Update: The dollar has settled to a consolidation »

FX Update: The dollar has…

02:10
07/17/19
07/17
02:10
07/17/19
02:10
General news
Asian Market Wrap: »

Asian Market Wrap:…

ATEX

Anterix

$46.95

-0.66 (-1.39%)

21:10
07/16/19
07/16
21:10
07/16/19
21:10
Syndicate
Anterix 2.22M share Secondary priced at $45.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 17

    Jul

TNXP

Tonix Pharmaceuticals

$0.57

-0.4087 (-41.75%)

21:08
07/16/19
07/16
21:08
07/16/19
21:08
Syndicate
Tonix Pharmaceuticals 9M share Secondary priced at $0.60 »

Aegis is acting as sole…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Jul

HTHT

Huazhu Group

$34.88

0.23 (0.66%)

21:05
07/16/19
07/16
21:05
07/16/19
21:05
Earnings
Huazhu Group sees Q2 revenue growth of 13%-15% »

Reports Q2 blended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PS

Pluralsight

$30.66

-0.71 (-2.26%)

20:58
07/16/19
07/16
20:58
07/16/19
20:58
Initiation
Pluralsight initiated at KeyBanc »

Pluralsight initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

TWOU

2U

$38.60

-0.34 (-0.87%)

20:57
07/16/19
07/16
20:57
07/16/19
20:57
Initiation
2U initiated at KeyBanc »

2U initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BVN

Buenaventura

$16.31

-0.03 (-0.18%)

20:36
07/16/19
07/16
20:36
07/16/19
20:36
Hot Stocks
Buenaventura reports Q2 Orcopampa gold production 10.7K oz vs. 5.9K in Q1 »

The company also lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

HOPE

Hope Bancorp

$13.96

0.2 (1.45%)

20:33
07/16/19
07/16
20:33
07/16/19
20:33
Hot Stocks
Hope Bancorp authorizes $50M stock repurchase program »

Hope Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

20:25
07/16/19
07/16
20:25
07/16/19
20:25
Conference/Events
CLSA Asian tech analyst team to hold an analyst/industry conference call »

Asian Technology Analysts…

BAC

Bank of America

$28.99

-0.23 (-0.79%)

, ABT

Abbott

$83.11

-0.69 (-0.82%)

20:25
07/16/19
07/16
20:25
07/16/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$28.99

-0.23 (-0.79%)

ABT

Abbott

$83.11

-0.69 (-0.82%)

USB

U.S. Bancorp

$53.04

-0.07 (-0.13%)

PNC

PNC Financial

$138.66

-1.52 (-1.08%)

PGR

Progressive

$84.11

0.105 (0.12%)

BK

BNY Mellon

$43.13

-0.02 (-0.05%)

OMC

Omnicom

$84.08

0.065 (0.08%)

TXT

Textron

$54.02

0.59 (1.10%)

CMA

Comerica

$71.75

0.39 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 26

    Aug

  • 06

    Sep

  • 16

    Oct

SCGLY

Societe Generale

$0.00

(0.00%)

20:08
07/16/19
07/16
20:08
07/16/19
20:08
Upgrade
Societe Generale rating change at JPMorgan »

Societe Generale upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$299.75

-1.03 (-0.34%)

, SPX

S&P 500

$0.00

(0.00%)

20:06
07/16/19
07/16
20:06
07/16/19
20:06
Periodicals
SF Fed President Daly not leaning in either direction on rates, Reuters says »

In a Reuters interview,…

SPY

SPDR S&P 500 ETF Trust

$299.75

-1.03 (-0.34%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAFD

Washington Federal

$34.63

0.02 (0.06%)

20:02
07/16/19
07/16
20:02
07/16/19
20:02
Earnings
Washington Federal reports Q3 EPS 67c, consensus 64c »

Reports Q3 NII $121.7M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$44.72

0.755 (1.72%)

19:16
07/16/19
07/16
19:16
07/16/19
19:16
Initiation
PagSeguro Digital initiated at Evercore ISI »

PagSeguro Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

, CTAS

Cintas

$239.46

-3.85 (-1.58%)

18:50
07/16/19
07/16
18:50
07/16/19
18:50
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

CTAS

Cintas

$239.46

-3.85 (-1.58%)

UAL

United Continental

$94.00

2.7 (2.96%)

QCOM

Qualcomm

$75.66

0.23 (0.30%)

NUS

Nu Skin

$45.50

1.44 (3.27%)

SENS

Senseonics

$1.68

-0.075 (-4.29%)

CSX

CSX

$79.57

1.05 (1.34%)

IBKR

Interactive Brokers

$50.72

-0.44 (-0.86%)

INO

Inovio

$3.00

0.05 (1.69%)

TELL

Tellurian

$7.68

-0.1 (-1.29%)

WB

Weibo

$41.57

-1.47 (-3.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

  • 31

    Jul

  • 06

    Aug

  • 07

    Aug

  • 26

    Aug

  • 09

    Sep

  • 13

    Nov

  • 18

    Jul

NVLN

Novelion Therapeutics

$0.71

-0.0054 (-0.75%)

18:46
07/16/19
07/16
18:46
07/16/19
18:46
Hot Stocks
Novelion Therapeutics announces BC Court dismissed action filed by Whitefort »

Novelion Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLGNF

Dialog Semiconductor

$0.00

(0.00%)

18:41
07/16/19
07/16
18:41
07/16/19
18:41
Earnings
Dialog Semiconductor raises Q2 revenue view to $482M »

Prior view was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHP

BHP Group

$57.59

-0.27 (-0.47%)

18:39
07/16/19
07/16
18:39
07/16/19
18:39
Hot Stocks
BHP Group reports Q4 iron ore output 63MT, down 2% from last year »

Reports FY19 iron ore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

DPZ

Domino's Pizza

$246.55

-23.42 (-8.68%)

18:33
07/16/19
07/16
18:33
07/16/19
18:33
Hot Stocks
Domino's Pizza CEO: We are in a position of strength »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 13

    Nov

UBER

Uber

$44.13

-0.38 (-0.85%)

18:18
07/16/19
07/16
18:18
07/16/19
18:18
Periodicals
Uber rolls out ride-hailing services in Hamburg, Germany, Reuters says »

Uber said it is rolling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

LFUS

Littelfuse

$168.35

-2.05 (-1.20%)

18:03
07/16/19
07/16
18:03
07/16/19
18:03
Earnings
Littelfuse reports preliminary Q2 EPS $1.91, consensus $2.03 »

Reports preliminary Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 19

    Sep

S

Sprint

$7.23

0.12 (1.69%)

, SSNLF

Samsung

$0.00

(0.00%)

17:51
07/16/19
07/16
17:51
07/16/19
17:51
Periodicals
Sprint says hackers broke into user accounts via Samsung site, ZDNet says »

Sprint (S) informed…

S

Sprint

$7.23

0.12 (1.69%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

17:50
07/16/19
07/16
17:50
07/16/19
17:50
Hot Stocks
Seattle Genetics up 8% to $68.20 after Q2 results »

The company achieved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 09

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.